“But if that's what you think why did you invest
Post# of 148148
I invested for monotherapy and then even more so for cancer, but that’s not the point of our discussion. The point is that the FDA is not to blame for the combo BLA delay. They’ve been working with CYDY to combine the 47 patient combo trial with data from the monotherapy trial in order to gain approval. That’s a groundbreaking approach. CYDY has been unable so far to meet their standard and is the fault of NP, the CEO, not the FDA.